IsoTis takes bone graft to US dental market:
This article was originally published in Clinica
Executive Summary
IsoTis OrthoBiologics has received US FDA 510(k) clearance to use its advanced synthetic bone graft material, OsSatura BCP, in dental applications. The company, which already markets in the US demineralised bone matrix (DBM) product range, said that the dental field represented a strong area of growth for IsoTis. The dental arena accounts for around 10% of the Lausanne, Switzerland firm's sales. The new dental product is composed of approximately 80% hydroxyapatite and 20% ss-tricalcium phosphate.